Quarterly report [Sections 13 or 15(d)]

IN-LICENSING AND ACQUISITION - Narrative (Details)

v3.25.1
IN-LICENSING AND ACQUISITION - Narrative (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Feb. 22, 2024
Jul. 31, 2024
Dec. 31, 2022
Jul. 31, 2022
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2022
Dec. 31, 2024
Asset Acquisition [Line Items]                
Acquisition-related liabilities         $ 5,000     $ 5,000
Research and development         8,436 $ 6,026    
Intangible asset         $ 26,512     $ 27,100
Forma                
Asset Acquisition [Line Items]                
Upfront fee       $ 2,000        
Research and development             $ 2,000  
Forma | Commercial milestones                
Asset Acquisition [Line Items]                
Potential payments       165,500        
Forma | Development and regulatory milestones                
Asset Acquisition [Line Items]                
Potential payments       $ 67,500        
Forma | Achievement of certain near-term regulatory milestone                
Asset Acquisition [Line Items]                
Research and development     $ 2,500          
GAVRETO (pralsetinib)                
Asset Acquisition [Line Items]                
Intangible assets, estimated useful life         12 years      
REZLIDHIA                
Asset Acquisition [Line Items]                
Intangible assets, estimated useful life         14 years      
REZLIDHIA | Forma | FDA approval and first commercial sale of product                
Asset Acquisition [Line Items]                
Intangible asset     $ 15,000       $ 15,000  
Blueprint | GAVRETO (pralsetinib)                
Asset Acquisition [Line Items]                
Asset acquisition, expected price $ 15,000              
Acquisition-related liabilities         $ 5,000      
Purchase consideration 15,400              
Acquisition payment 15,000 $ 10,000            
Transaction costs $ 400              
Blueprint | GAVRETO (pralsetinib) | Minimum                
Asset Acquisition [Line Items]                
Potential tiered royalties (as a percentage) 10.00%              
Blueprint | GAVRETO (pralsetinib) | Maximum                
Asset Acquisition [Line Items]                
Potential tiered royalties (as a percentage) 30.00%              
Blueprint | GAVRETO (pralsetinib) | First commercial sale                
Asset Acquisition [Line Items]                
Asset acquisition, expected price $ 10,000              
Blueprint | GAVRETO (pralsetinib) | First anniversary of the closing date                
Asset Acquisition [Line Items]                
Asset acquisition, expected price 5,000              
Blueprint | GAVRETO (pralsetinib) | Commercial milestones                
Asset Acquisition [Line Items]                
Potential milestone payments 97,500              
Blueprint | GAVRETO (pralsetinib) | Regulatory milestones                
Asset Acquisition [Line Items]                
Potential milestone payments $ 5,000